



DOCKET NO.: 220316US0PCT

RECEIVED  
APR 11 2003  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF:

Steven ARKINSTALL, ET AL.

SERIAL NO.: 10/<sup>088,090</sup>~~888,090~~

FILED: June 21, 2002

FOR: PHARMACEUTICALLY ACTIVE  
SULFONYL AMINO ACID  
DERIVATIVES

: GROUP ART UNIT: 1625

: EXAMINER: CHANG, Celia C.

*8/Election  
w/traverse*

*Bel  
4-22-03*

RESPONSE TO RESTRICTION AND ELECTION OF SPECIES REQUIREMENT

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

SIR:

Responsive to the Official Action dated March 10, 2003, Applicants elect, with traverse, Group I, Claims 7-8 and 24-25, for further prosecution. In addition, Applicants elect, with traverse, the compound of example 1 (page 27, lines 18-19 of the specification), 4-chloro-N-({5-[(2-[(2-([3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino)-ethyl]amino)-2-oxoethyl]amino)sulfonyl]thien-2-yl}methyl) benzamide as a single disclosed species. Claims 1-4, 6-7, 9-21, 23-28 read on the elected species. Claims 1-4, 6-7, 10-21, 23-24, and 26-28 are generic.

REMARKS

The Office has required restriction in the present application as follows:

Group I: Claims 7-8 and 24-25, drawn to compounds wherein R<sup>5</sup> and R<sup>6</sup> are independent substituents; and